Selects the aldosterone-to-renin ratio (ARR) method over hypokalemia for screening hypertensive patients for primary aldosteronism. Use when a clinician asks what test to use for screening hypertensive patients with resistant hypertension or unexplained hypokalemia for PA.
Scanned 9/9/2026
Install to Claude Code
npx -y skills add dromlakhani/MD2SKILL --skill endo-pa-screening-method-arr --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Endo Pa Screening Method Arr?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-endo-pa-screening-method-arr)More formats (shields.io, HTML) on the badges page.
---
name: endo-pa-screening-method-arr
description: Selects the aldosterone-to-renin ratio (ARR) method over hypokalemia for screening hypertensive patients for primary aldosteronism. Use when a clinician asks what test to use for screening hypertensive patients with resistant hypertension or unexplained hypokalemia for PA.
---
# Use aldosterone-to-renin ratio for PA screening
## STEP 1 — Gather Information
Collect seated morning blood sample for aldosterone and plasma renin activity (PRA) or direct renin concentration (DRC), serum potassium, and review current medications; ensure no dietary sodium restriction in prior days.
→ Proceed to measure aldosterone and renin.
## STEP 2 — Rule In / Rule Out
Assess renin suppression: PRA ≤1 ng/mL/h or DRC ≤8.2 mU/L.
If not suppressed → screen negative, rule out PA.
If suppressed → proceed to evaluate aldosterone level and ARR.
## STEP 3 — Classify or Stratify
Calculate ARR: aldosterone (ng/dL) ÷ PRA (ng/mL/h) or aldosterone (pmol/L) ÷ DRC (mU/L).
Apply cutoffs:
- Immunoassay: aldosterone ≥10 ng/dL **and** ARR >20
- LC-MS/MS: aldosterone ≥7.5 ng/dL **and** ARR >15 (≈25% lower threshold)
If both criteria met → screen positive; otherwise → screen negative.
→ Classify screen result.
## STEP 4 — Decide
If screen positive → order aldosterone suppression testing for confirmation before PA-specific therapy.
If screen negative but hypokalemia present → correct potassium to reference range and repeat screen.
→ Initiate confirmatory testing or repeat screening as appropriate.
## Clinical Guardrails / Mimics / Pitfalls
Do not rely on hypokalemia alone for screening; do not ignore interfering medications (e.g., β-blockers, ACEi/ARBs) without per Table 6/7 strategies; do not screen during sodium restriction; do not use ARR cutoffs without adjusting for assay type (immunoassay vs LC-MS/MS); do not forget to measure potassium to avoid falsely low aldosterone interpretation.
## Concrete Clinical Example
A 55-year-old with resistant hypertension (BP 168/94 mmHg) and K+ 3.9 mmol/L has seated morning aldosterone 14 ng/dL (immunoassay) and PRA 0.3 ng/mL/h → ARR 46.7 (>20) → screen positive → proceed to aldosterone suppression testing.
**Source:** Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2025, https://doi.org/10.1210/clinem/dgaf284
> **TODO:** consider adding scripts/calc.py for the endo-pa-screening-method-arr calculator
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!